Brookline initiated coverage of Opus Genetics (IRD) with a Buy rating and $8 price target
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics initiated with an Overweight at Piper Sandler
- Buy These 3 Penny Stocks Now, Say Five-Star Analysts
- Opus Genetics doses first participant in OPGx-BEST1 Phase 1/2 trial
- Promising Advancements in Opus Genetics’ Retinal Disease Platform Support Buy Rating
- Opus Genetics: Buy Rating Backed by Strong Financials, Regulatory Support, and Promising Study Progress